FDA Requests Input on Ibogaine Trial Design for OUD and PTSD

FDA Opens Public Docket on Ibogaine Clinical Trials

The U.S. Food and Drug Administration (FDA) has formally issued a Request for Information (RFI) on October 6, 2026, seeking public input on the design and safety considerations for clinical trials involving ibogaine drug products. This RFI, published in the Federal Register, signals the agency’s intent to establish clear standards for the clinical development of ibogaine, particularly for opioid use disorder (OUD) and post-traumatic stress disorder (PTSD). The FDA’s action follows its earlier guidance on psychedelic drug investigations and reflects a new phase of federal engagement, as the Department of Health and Human Services (HHS) is now funding the first federally supported ibogaine trials in adults with OUD and PTSD.

Mechanism and Context: Why Ibogaine, and Why Now?

Ibogaine, a psychoactive alkaloid derived from the West African shrub Tabernanthe iboga, has been studied internationally for its potential to interrupt substance use disorders, particularly opioid dependence. Despite anecdotal reports and small-scale studies suggesting possible efficacy, ibogaine’s development has been hampered by significant cardiac risks, lack of standardized dosing protocols, and its Schedule I status under the Controlled Substances Act. The FDA’s RFI specifically requests data and perspectives on protocol elements such as dose selection and escalation, care setting, safety monitoring, eligibility criteria, stopping rules, and safety oversight. This approach is notable because it directly solicits granular, trial-level input from researchers, clinicians, and the public, rather than issuing top-down prescriptive guidance at this stage.

Unlike previous psychedelic research initiatives, this RFI is explicitly linked to federal funding streams and signals a willingness to consider ibogaine within the broader context of national responses to the opioid crisis and post-traumatic stress among veterans and civilians. This development could also serve as a template for how the FDA will approach other high-risk, high-potential psychedelic compounds in the future.

Implications for Policy, Research, and Industry

The FDA’s request for input is likely to shape not only the design of the first federally supported ibogaine trials, but also the regulatory expectations for all future Investigational New Drug (IND) applications involving ibogaine. Stakeholders—including academic researchers, clinical trial sponsors, and industry operators—are now invited to submit comments and data to Docket No. FDA-2026-N-2042 by the specified deadline. Key areas of focus include:

• Dose selection and escalation: Determining safe and effective dosing regimens in populations with high medical comorbidity.
• Care setting and safety monitoring: Defining requirements for cardiac monitoring, emergency response, and inpatient versus outpatient administration.
• Eligibility and exclusion criteria: Balancing access with risk mitigation, especially for individuals with preexisting cardiac conditions or polysubstance use.
• Stopping rules and oversight: Establishing clear criteria for trial interruption in response to adverse events.

For the research community, this RFI offers an unusual opportunity to influence the regulatory framework at an early stage. For industry, the FDA’s engagement reduces uncertainty around the pathway to IND approval, but also raises the bar for safety and protocol rigor. Notably, the FDA’s move may accelerate the entry of new sponsors and increase competition for federal research funding in the psychedelic space.

Risks, Unknowns, and Real-World Failure Modes

Ibogaine’s cardiac toxicity, particularly its potential to prolong the QT interval and induce fatal arrhythmias, remains the most significant barrier to clinical development. The FDA’s RFI explicitly seeks data on safety monitoring and stopping rules, reflecting concern over real-world failure modes observed in unsupervised or poorly monitored settings abroad. Another non-obvious challenge is the lack of standardized manufacturing and quality control for ibogaine, which complicates dose reproducibility and cross-trial comparisons. Additionally, the agency’s openness to public comment introduces the risk that well-intentioned but poorly substantiated claims could influence the regulatory process, underscoring the need for rigorous, evidence-based submissions.

Unanswered questions include whether the FDA will ultimately require inpatient cardiac telemetry for all trial participants, how to manage the risk of polysubstance withdrawal during ibogaine administration, and whether unique informed consent procedures will be mandated due to the drug’s psychoactive and medical risk profile.

Looking Ahead: Shaping the Future of Psychedelic Regulation

The FDA’s RFI on ibogaine clinical trial design is a watershed moment for U.S. psychedelic research and policy. By inviting broad input on trial safety and design, the agency is not only advancing the science of ibogaine but also setting a precedent for how emerging psychedelic therapies may be evaluated and regulated. The outcome of this process will likely influence both federal research priorities and the commercial landscape for years to come. Stakeholders should closely monitor the docket, participate in the comment process, and prepare for a regulatory environment that will demand both innovation and rigorous safety standards. The FDA’s approach here may also serve as a model for future regulatory engagement with other high-risk, high-potential compounds in the psychedelic class.

How we research: This article was written by Dr. Jamie L. McCarthy, PhD (Neuropharmacology), and reviewed by Dr. Rachel Kim, MD, on 2026-10-10. Primary sources include the official Federal Register notice and FDA regulatory guidance.